Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNYSE:AMPENASDAQ:CALANASDAQ:CRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shs30,000 shsAMPEAmpio Pharmaceuticals$0.00+3,900.0%$0.02$0.00▼$0.45$5K4.76589 shs272 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.05N/A-2.8213,560 shs1,253 shsCRMECardiome Pharma$2.33$0.00$1.29▼$4.84N/AN/A135,322 shs90,444 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-8.70%-14.43%-62.12%-80.94%AMPEAmpio Pharmaceuticals+3,900.00%+48.15%-96.93%+566.67%-96.00%CALACalithera Biosciences0.00%-90.00%-95.00%-90.00%-99.00%CRMECardiome Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals0.1492 of 5 stars0.03.00.00.00.00.00.6CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACRMECardiome PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ACRMECardiome Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACRMECardiome PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACRMECardiome PharmaN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACRMECardiome PharmaN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/ACRMECardiome Pharma50.49%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%CRMECardiome PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableCRMECardiome PharmaN/AN/AN/AOptionableCRME, AEHAW, AMPE, and CALA HeadlinesRecent News About These CompaniesCramer's Lightning Round: Vertex Pharmaceuticals is a buyOctober 31, 2024 | nbclosangeles.comN35 True-Crime Series to Binge Right NowAugust 13, 2024 | hollywoodreporter.comHWhy Ramdev, vaccine producing pharma companies and government are all at faultMay 6, 2024 | counterview.netCAmphastar Pharmaceuticals (FRA:29A) Price Target Increased by 46.10% to 60.45August 13, 2023 | nasdaq.comCROUERE: Big Pharma Is Just As Woke As Bud LightAugust 3, 2023 | thehayride.comTCrime and CourtsJuly 8, 2023 | thegazette.comTCroma-Pharma reports revenue growthMay 10, 2023 | poandpo.comPExpert Analysis on Pharmaceutical Rubber Stoppers Market by 2023-2030March 25, 2023 | marketwatch.comCommission to seek patient-centred, industry-friendly pharma rules reformMarch 18, 2023 | euractiv.comEGlenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mgFebruary 17, 2023 | msn.comPharmacy Career Conference returned in its 4th edition to assist and inspire pharmacy students and industry professionalsFebruary 12, 2023 | msn.comPharma sector growth healthy after Covid tooFebruary 1, 2023 | msn.comMark Cuban's pharmaceuticals startup ties up with RxPreferredJanuary 11, 2023 | gazette.comGPharma Millionaire Who Killed 8-Year-Old Son in Manhattan Hotel Room Found DeadJanuary 5, 2023 | nbcnewyork.comNYaral Pharma Launches Diclofenac Epolamine Topical System 1.3%January 4, 2023 | joplinglobe.comJDOJ sues pharma giant AmerisourceBergen Corp. for allegedly helping to fuel the opioid epidemicDecember 29, 2022 | cbsnews.comAcute Coronary Syndrome Therapeutics Market Size in Pharma & Healthcare Sector is Growing Quickly with Analysis by Top Key players till 2028November 2, 2022 | marketwatch.comPharmaceutical Fine Chemicals Category Is Projected to Grow at a CAGR of 5.86% by 2026, SpendEdge ReportsOctober 20, 2022 | yahoo.comJenny Sundqvist new CEO of InDex PharmaceuticalsOctober 13, 2022 | finance.yahoo.com1SOMAÍ Pharmaceuticals Opens Medical Cannabis Manufacturing Facility In PortugalSeptember 28, 2022 | benzinga.comNew MarketBeat Followers Over TimeCRME, AEHAW, AMPE, and CALA Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0091 0.00 (0.00%) As of 07/3/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Ampio Pharmaceuticals NYSE:AMPE$0.0040 +0.00 (+3,900.00%) As of 07/7/2025 01:24 PM EasternAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/7/2025 12:25 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Cardiome Pharma NASDAQ:CRMECardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
